RxDoctor Payments Data

Naomi Quezada

Family · Albuquerque, NMNPI 1376150037

Payments from drug & device makers

$1,704in general payments, 2019–2025

Across 75 payments — averaging $22.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$387
  • Lilly USA, LLC$273
  • Exact Sciences$159
  • GSK$154
  • Bayer$145
  • Boehringer Ingelheim$128
  • plus $457 from 11 others

What the payments were for

  • Food & beverage$1,704100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,704 in reported general payments places this provider in the 85th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$41,055
Medicare patients
123
Services billed
563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin90$80,826
OzempicSemaglutide50$46,031
EliquisApixaban31$38,758
TrulicityDulaglutide26$21,984
LinzessLinaclotide34$20,619
MounjaroTirzepatide16$15,585
RybelsusSemaglutide11$10,125
Incruse ElliptaUmeclidinium Bromide15$6,944
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$6,282
Novolog FlexpenInsulin Aspart15$4,500
Albuterol Sulfate HfaAlbuterol Sulfate81$2,632
Atorvastatin Calcium175$2,416
Levothyroxine Sodium175$2,391
Tamsulosin Hcl116$2,000
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$1,931

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$128$80,82690 claims
Novo NordiskOzempic, Rybelsus$387$56,15661 claims
PfizerEliquis$121$38,75831 claims
Lilly USA, LLCTrulicity, Mounjaro$273$37,56942 claims
AbbVieLinzess, Synthroid$24$21,35554 claims
GSKIncruse Ellipta$154$6,94415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,080 family providers in New Mexico.

Other family in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →